Browse treatments

…hanisms and consistent placebo outcomes, they may be considered CETAs for ES-SCLC first-line treatment, despite potential OS bias fro…

…Background and Importance The preparation of parenteral nutrition (PN) is an important hospital process. Traditionally, PN prepar…

…Importance The need to optimise the production of drugs used in cancer treatment, as well as reduce the length of time patients spend in hospita…

…e increased significantly in recent decades, driving demand for anti-vascular endothelial growth factor (VEGF) therapies. Compounding these agents into prefilled syringes optimises res…

…linical trials (CTs), which focus on the safety and dosage of a new treatment, can affect the reliability of the data, patient safety and the…

…aceutical consultations enhance the safety and effectiveness of long-term antibiotic therapies by improving patient understanding, supporting adherence, and e…

…reas, many patients must travel long distances to collect their treatments, generating carbon dioxide (CO 2) emissions, with the consequen…

… were included (53.0% male, mean age 43.5 ± 13.0). Most were on anti-TNF therapy (81.0%) and first-line treatment (53.4%). At baseline, 35.3% ha…

…f care and may be adapted across healthcare systems to optimise pharmacotherapy outcomes.Conflict of Interest No conflict of interest…

…elium alterations, and progressive visual impairment. Off-label photodynamic therapy (PDT) with verteporfin has emerged as a potential treatment for…

…0.5 mcg/kg/min, with further reductions in hepatic dysfunction. Extracorporeal support did not significantly alter dosing requirements, reinforcing he…

…sponsible for 90% of cases of severe vision loss, benefits from anti-angiogenic therapy, mainly aflibercept and bevacizumab, with faricimab as a second…